Results for the Second Quarter & First Half 2026
Medistim delivers record first-half revenue and record EBIT in Q2 2026
Medistim ASA today announced its financial results for the second quarter and first half of 2026. Sales revenue for the quarter ended at MNOK 202.0, up 19.5% (currency-neutral growth of own products of 33.6%), with broad-based growth across all regions: AMERICAS up 46.3%, APAC up 22.4%, and EMEA up 19.4% on a currency-neutral basis. This brought first-half revenue to a record MNOK 403.7, a 15.1% increase. Operating profit (EBIT) for the quarter grew 20.6% to MNOK 65.3, corresponding to a 32.3% EBIT margin, bringing first-half EBIT to a record MNOK 122.4, up 8.0%, with a 30.3% margin.
The second quarter also marked the first quarter of direct sales to end customers in Japan, following the establishment of Medistim's direct sales operation there in March 2026. The company maintains a solid financial position with no interest-bearing bank loans, after paying a dividend of NOK 8.00 per share (MNOK 146.3) in May. The Board will propose that the General Meeting authorize the distribution of quarterly dividends.
Read the full Q2 and H1 2026 financial report and watch the webinar presentation of the results here: Medistim Q2 & H1 Results
